189 related articles for article (PubMed ID: 9621480)
1. Cardiotoxicity and cardioprotection in breast cancer chemotherapy. The role of dexrazoxane.
Venturini M
Clin Ter; 1998; 149(921):5-6. PubMed ID: 9621480
[No Abstract] [Full Text] [Related]
2. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
3. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
4. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
7. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum RH
Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
[No Abstract] [Full Text] [Related]
8. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Lipshultz SE
J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739
[No Abstract] [Full Text] [Related]
9. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff BB; Herman EH
Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
[TBL] [Abstract][Full Text] [Related]
10. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Hellmann K
J Clin Oncol; 1996 Feb; 14(2):332-3. PubMed ID: 8636740
[No Abstract] [Full Text] [Related]
12. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
[No Abstract] [Full Text] [Related]
13. Cardiotoxicity and cardioprotection during chemotherapy.
Hochster H; Wasserheit C; Speyer J
Curr Opin Oncol; 1995 Jul; 7(4):304-9. PubMed ID: 7578376
[TBL] [Abstract][Full Text] [Related]
14. Drug may protect children's hearts from chemotherapy.
McBride D
ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
[No Abstract] [Full Text] [Related]
15. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
16. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
17. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
18. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
20. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Gershanovich ML
Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
